Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma
NCT05508347Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2022
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Sichuan Cancer Hospital. Started Apr 2022; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05508347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508347.